NO333747B1 - Vat maleprosess - Google Patents

Vat maleprosess Download PDF

Info

Publication number: NO333747B1
Authority: NO; Norway
Prior art keywords: mill; drug substance; chamber; ppm; finely divided
Prior art date: 2000-06-28

Application number

NO20026120A

Other languages

English (en)

Norwegian (no)

Other versions

NO20026120D0 (no

NO20026120L (no

Inventor

Simon Joseph Holland

Wendy Anne Knight

Graham Stanley Leonard

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-28

Filing date

2002-12-19

Publication date

2013-09-09

2000-06-28 Priority claimed from GB0015856A external-priority patent/GB0015856D0/en

2001-05-22 Priority claimed from GB0112496A external-priority patent/GB0112496D0/en

2002-12-19 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2002-12-19 Publication of NO20026120D0 publication Critical patent/NO20026120D0/no

2003-01-27 Publication of NO20026120L publication Critical patent/NO20026120L/no

2013-09-09 Publication of NO333747B1 publication Critical patent/NO333747B1/no

Links

238000007591 painting process Methods 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 60
229940088679 drug related substance Drugs 0.000 claims abstract description 48
239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 45
229920001778 nylon Polymers 0.000 claims abstract description 37
239000004677 Nylon Substances 0.000 claims abstract description 35
238000002360 preparation method Methods 0.000 claims abstract description 33
238000011109 contamination Methods 0.000 claims abstract description 29
239000000314 lubricant Substances 0.000 claims abstract description 29
239000000725 suspension Substances 0.000 claims abstract description 21
238000013019 agitation Methods 0.000 claims abstract description 13
238000001238 wet grinding Methods 0.000 claims description 11
239000007787 solid Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 6
238000001035 drying Methods 0.000 claims description 5
239000004610 Internal Lubricant Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000010687 lubricating oil Substances 0.000 claims description 2
238000010422 painting Methods 0.000 abstract description 7
239000011324 bead Substances 0.000 description 38
239000002245 particle Substances 0.000 description 24
239000002609 medium Substances 0.000 description 21
239000003814 drug Substances 0.000 description 18
229940079593 drug Drugs 0.000 description 17
239000000203 mixture Substances 0.000 description 15
229910052727 yttrium Inorganic materials 0.000 description 10
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 10
239000007788 liquid Substances 0.000 description 9
239000006185 dispersion Substances 0.000 description 8
238000000227 grinding Methods 0.000 description 7
238000002156 mixing Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 6
RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 6
238000012545 processing Methods 0.000 description 6
239000007921 spray Substances 0.000 description 6
229910001928 zirconium oxide Inorganic materials 0.000 description 6
230000008901 benefit Effects 0.000 description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
239000006194 liquid suspension Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000012907 medicinal substance Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000001694 spray drying Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
229910000831 Steel Inorganic materials 0.000 description 3
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000003801 milling Methods 0.000 description 3
239000003973 paint Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
239000002002 slurry Substances 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000010959 steel Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KCXZNSGUUQJJTR-UHFFFAOYSA-N Di-n-hexyl phthalate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCC KCXZNSGUUQJJTR-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000004891 communication Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000002296 dynamic light scattering Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
229960004270 nabumetone Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
239000004810 polytetrafluoroethylene Substances 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000004064 recycling Methods 0.000 description 2
239000004576 sand Substances 0.000 description 2
VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 2
238000005549 size reduction Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
229910002076 stabilized zirconia Inorganic materials 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
229910052726 zirconium Inorganic materials 0.000 description 2
SIXWIUJQBBANGK-UHFFFAOYSA-N 4-(4-fluorophenyl)-1h-pyrazol-5-amine Chemical compound N1N=CC(C=2C=CC(F)=CC=2)=C1N SIXWIUJQBBANGK-UHFFFAOYSA-N 0.000 description 1
GPZYYYGYCRFPBU-UHFFFAOYSA-N 6-Hydroxyflavone Chemical compound C=1C(=O)C2=CC(O)=CC=C2OC=1C1=CC=CC=C1 GPZYYYGYCRFPBU-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229910052684 Cerium Inorganic materials 0.000 description 1
229920002943 EPDM rubber Polymers 0.000 description 1
229920002449 FKM Polymers 0.000 description 1
JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
229920000571 Nylon 11 Polymers 0.000 description 1
229920000299 Nylon 12 Polymers 0.000 description 1
229920003189 Nylon 4,6 Polymers 0.000 description 1
229920002292 Nylon 6 Polymers 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
239000004696 Poly ether ether ketone Substances 0.000 description 1
208000034809 Product contamination Diseases 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000498 ball milling Methods 0.000 description 1
238000010296 bead milling Methods 0.000 description 1
JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
150000001562 benzopyrans Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
-1 carbohydrates Chemical compound 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
238000004814 ceramic processing Methods 0.000 description 1
ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000000976 ink Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
RCLXAPJEFHPYEG-MSOLQXFVSA-N n-[(3s,4r)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide Chemical compound N([C@H]1[C@H](O)C(C)(C)OC2=CC=C(C=C21)C(=O)C)C(=O)C1=CC=C(F)C=C1 RCLXAPJEFHPYEG-MSOLQXFVSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000012771 pancakes Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000012169 petroleum derived wax Substances 0.000 description 1
235000019381 petroleum wax Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002530 polyetherether ketone Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/16—Mills in which a fixed container houses stirring means tumbling the charge
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/16—Mills in which a fixed container houses stirring means tumbling the charge
- B02C17/163—Stirring means
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/18—Details
- B02C17/22—Lining for containers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catching Or Destruction (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Disintegrating Or Milling (AREA)
Grinding-Machine Dressing And Accessory Apparatuses (AREA)

NO20026120A 2000-06-28 2002-12-19 Vat maleprosess NO333747B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0015856A GB0015856D0 (en)	2000-06-28	2000-06-28	Wet milling process
GB0112496A GB0112496D0 (en)	2001-05-22	2001-05-22	Wet milling process
PCT/EP2001/007085 WO2002000196A2 (en)	2000-06-28	2001-06-22	Wet milling process

Publications (3)

Publication Number	Publication Date
NO20026120D0 NO20026120D0 (no)	2002-12-19
NO20026120L NO20026120L (no)	2003-01-27
NO333747B1 true NO333747B1 (no)	2013-09-09

Family

ID=26244560

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20026120A NO333747B1 (no)	2000-06-28	2002-12-19	Vat maleprosess

Country Status (24)

Country	Link
US (2)	US20040089753A1 (cs)
EP (1)	EP1294358B1 (cs)
JP (1)	JP4188078B2 (cs)
KR (1)	KR100786927B1 (cs)
CN (1)	CN1321628C (cs)
AR (1)	AR029284A1 (cs)
AT (1)	ATE273695T1 (cs)
AU (2)	AU2002215608B2 (cs)
BR (1)	BR0111747A (cs)
CA (1)	CA2413330A1 (cs)
CZ (1)	CZ303572B6 (cs)
DE (1)	DE60105023T2 (cs)
ES (1)	ES2225624T3 (cs)
HU (1)	HU230396B1 (cs)
IL (2)	IL153231A0 (cs)
MX (1)	MXPA03000051A (cs)
MY (1)	MY128806A (cs)
NO (1)	NO333747B1 (cs)
NZ (1)	NZ522783A (cs)
PL (1)	PL202623B1 (cs)
PT (1)	PT1294358E (cs)
SI (1)	SI1294358T1 (cs)
TW (1)	TWI290836B (cs)
WO (1)	WO2002000196A2 (cs)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001296193B2 (en) *	2000-10-20	2006-04-27	Biovitrum Ab	2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
GB0112497D0 (en) *	2001-05-22	2001-07-11	Smithkline Beecham Plc	Formulation
GB0206200D0 (en) *	2002-03-15	2002-05-01	Glaxo Group Ltd	Pharmaceutical compositions
GB0209022D0 (en)	2002-04-19	2002-05-29	Imp College Innovations Ltd	Compounds
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
US7140567B1 (en) *	2003-03-11	2006-11-28	Primet Precision Materials, Inc.	Multi-carbide material manufacture and use as grinding media
MXPA05013850A (es)	2003-06-17	2006-05-17	Phibro Tech Inc	Conservador particulado para madera y metodo para producir el mismo.
GB0320522D0 (en) *	2003-09-02	2003-10-01	Glaxo Group Ltd	Formulation
JP5460947B2 (ja)	2003-09-03	2014-04-02	グラクソグループリミテッド	新規調製方法、塩、組成物及び使用
US20050252408A1 (en) *	2004-05-17	2005-11-17	Richardson H W	Particulate wood preservative and method for producing same
US7578455B2 (en) *	2004-08-09	2009-08-25	General Motors Corporation	Method of grinding particulate material
EP2431430B1 (en)	2004-10-14	2017-02-01	Koppers Performance Chemicals Inc.	The use of micronized wood preservative formulations in organic carriers
EP1839502A4 (en) *	2004-12-07	2010-03-24	Ajinomoto Kk	FINE AMINO ACID POWDER AND SUSPENSION THEREOF
US8703099B2 (en)	2005-02-24	2014-04-22	Dr Pharma Nova, Llc	Registry method and control system for DEA schedule II-V medicines
JP2008540503A (ja)	2005-05-10	2008-11-20	グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ	細菌感染症の処置に有用なエーテル結合マクロライド
PL1879573T3 (pl)	2005-05-10	2013-05-31	Incyte Holdings Corp	Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
EP2270014A1 (en)	2005-09-22	2011-01-05	Incyte Corporation	Azepine inhibitors of janus kinases
EP2455382B1 (en)	2005-12-13	2016-10-26	Incyte Holdings Corporation	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CA2634198C (en)	2005-12-20	2014-06-03	Incyte Corporation	N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0600928D0 (en)	2006-01-17	2006-02-22	Novacta Biosystems Ltd	Improvements relating to lantibiotics
DE102006028590A1 (de) *	2006-06-22	2007-12-27	Forschungszentrum Karlsruhe Gmbh	Vorrichtung und Verfahren zur Herstellung keramischer Granulate
KR20090025262A (ko)	2006-06-23	2009-03-10	인사이트 코포레이션	Ｈｍ７４ａ 아고니스트로서 푸리논 유도체
WO2007150025A2 (en)	2006-06-23	2007-12-27	Incyte Corporation	Purinone derivatives as hm74a agonists
US7828543B2 (en) *	2006-07-27	2010-11-09	Casa Herrera, Inc.	Dough sheeter cutter roller
US7683060B2 (en)	2006-08-07	2010-03-23	Incyte Corporation	Triazolotriazines as kinase inhibitors
JP2010501591A (ja)	2006-08-23	2010-01-21	インテレクト・ニューロサイエンシズ・インコーポレーテッド	３−（３−インドリル）プロピオン酸カルシウム塩およびそれから３−（３−インドリル）プロピオン酸の遊離酸を作る方法
ES2444574T3 (es)	2006-09-19	2014-02-25	Incyte Corporation	N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
CL2007002650A1 (es)	2006-09-19	2008-02-08	Incyte Corp	Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP2121692B1 (en)	2006-12-22	2013-04-10	Incyte Corporation	Substituted heterocycles as janus kinase inhibitors
US7883039B2 (en) *	2007-02-27	2011-02-08	Collette Nv	Continuous granulating and drying apparatus including measurement units
JP2008235481A (ja) *	2007-03-19	2008-10-02	Nippon Chem Ind Co Ltd	半導体ウエハ研磨用組成物、その製造方法、及び研磨加工方法
EP3070090B1 (en)	2007-06-13	2018-12-12	Incyte Holdings Corporation	Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CL2008001839A1 (es)	2007-06-21	2009-01-16	Incyte Holdings Corp	Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GB0714029D0 (en)	2007-07-18	2007-08-29	Novacta Biosystems Ltd	Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en)	2007-07-18	2007-08-29	Novacta Biosystems Ltd	The use of type-B lantibiotic-based compounds having antimicrobial activity
PT2178858E (pt)	2007-08-02	2012-02-24	Recordati Ireland Ltd	Novos compostos heterocíclicos como antagonistas de mglu5
WO2009064835A1 (en)	2007-11-16	2009-05-22	Incyte Corporation	4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US8158616B2 (en)	2008-03-11	2012-04-17	Incyte Corporation	Azetidine and cyclobutane derivatives as JAK inhibitors
WO2009132202A2 (en)	2008-04-24	2009-10-29	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
WO2009143211A2 (en)	2008-05-21	2009-11-26	Incyte Corporation	Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
PL2315756T3 (pl)	2008-07-08	2015-02-27	Incyte Holdings Corp	1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
WO2010090680A1 (en)	2008-12-15	2010-08-12	Wyeth Llc	Substituted oxindole cb2 agonists
WO2010077839A1 (en)	2008-12-15	2010-07-08	Wyeth Llc (Formerly Known As Wyeth)	Substituted oxindol cb2 agonists for pain treatment
US8436008B2 (en)	2008-12-22	2013-05-07	Incyte Corporation	Substituted heterocyclic compounds
SI2387580T1 (sl)	2009-01-14	2014-11-28	Novacta Biosystems Limited	Deoksiaktagardinski derivati
GB0900599D0 (en)	2009-01-14	2009-02-18	Novacta Biosystems Ltd	Treatment
US8765727B2 (en)	2009-01-23	2014-07-01	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
WO2010087447A1 (ja) *	2009-01-30	2010-08-05	明治製菓株式会社	微粉砕医薬組成物
WO2010089119A1 (en)	2009-02-04	2010-08-12	Recordati Ireland Limited	Heterocyclic derivatives as m-glu5 antagonists
MX2011008043A (es)	2009-02-04	2011-08-17	Novacta Biosystems Ltd	Derivados de actagardina.
CA2752150A1 (en)	2009-02-11	2010-08-19	Reaction Biology Corp.	Selective kinase inhibitors
WO2010100477A2 (en)	2009-03-03	2010-09-10	Shire Llc	Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US8481732B2 (en)	2009-03-20	2013-07-09	Incyte Corporation	Substituted heterocyclic compounds
EP2413937A1 (en)	2009-04-02	2012-02-08	Shire LLC	Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
JP5775070B2 (ja)	2009-05-22	2015-09-09	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
SG176111A1 (en)	2009-05-22	2011-12-29	Incyte Corp	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
CN102596896A (zh)	2009-06-24	2012-07-18	夏尔有限责任公司	美西律氨基酸和肽前药以及它们的用途
CN104945420A (zh)	2009-06-29	2015-09-30	因塞特公司	作为pi3k抑制剂的嘧啶酮类
AU2010272233A1 (en)	2009-07-17	2012-02-09	Shire Llc	Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
CA2768668A1 (en)	2009-07-23	2011-01-27	Shire Llc	Galantamine amino acid and peptide prodrugs and uses thereof
WO2011022393A2 (en)	2009-08-17	2011-02-24	The Brigham And Women's Hospital, Inc.	Phosphatidylcholine transfer protein inhibitors
AR078012A1 (es)	2009-09-01	2011-10-05	Incyte Corp	Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
US20120028931A1 (en)	2009-09-14	2012-02-02	Recordati Ireland Limited	Heterocyclic m-glu5 antagonists
GB0916163D0 (en)	2009-09-15	2009-10-28	Shire Llc	Prodrugs of guanfacine
KR101921850B1 (ko)	2009-10-09	2018-11-23	인사이트 홀딩스 코포레이션	3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
US8680108B2 (en)	2009-12-18	2014-03-25	Incyte Corporation	Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
US20110190267A1 (en)	2010-01-05	2011-08-04	Shire Pharmaceuticals, Inc.	Prodrugs of opioids and uses thereof
JP5852966B2 (ja)	2010-02-02	2016-02-03	ノヴァクタバイオシステムズリミティッド	ランチビオティックの塩
GB201001688D0 (en)	2010-02-02	2010-03-17	Novacta Biosystems Ltd	Compounds
EP2536729A1 (en)	2010-02-18	2012-12-26	Incyte Corporation	Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
PT3354652T (pt)	2010-03-10	2020-07-20	Incyte Holdings Corp	Derivados de piperidin-4-ilazetidina como inibidores de jak1
AR081823A1 (es)	2010-04-14	2012-10-24	Incyte Corp	DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
RS54824B1 (sr)	2010-05-21	2016-10-31	Incyte Holdings Corp	Topikalna formulacija za inhibiciju jak-a
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
EA023020B1 (ru)	2010-07-09	2016-04-29	Рекордати Айерленд Лимитед	Спирогетероциклические соединения и их применение в качестве антагонистов mglu5
GB201013509D0 (en)	2010-08-11	2010-09-22	Novacta Biosystems Ltd	Compounds
GB201013508D0 (en)	2010-08-11	2010-09-22	Novacta Biosystems Ltd	Compounds
GB201013507D0 (en)	2010-08-11	2010-09-22	Novacta Biosystems Ltd	Compounds
GB201013513D0 (en)	2010-08-11	2010-09-22	Novacta Biosystems Ltd	Formulations
NZ607000A (en)	2010-08-24	2015-02-27	Imp Innovations Ltd	Glycodendrimers of polypropyletherimine
ES2524892T3 (es)	2010-09-02	2014-12-15	Glaxosmithkline Intellectual Property Development Limited	2-(Benciloxi)benzamidas como inhibidores de LRRK2 quinasa
PH12013500501A1 (en)	2010-09-15	2013-05-06	Shire Llc	Prodrugs of guanfacine
WO2012046062A1 (en)	2010-10-05	2012-04-12	Shire, Llc	Use of prodrugs to avoid gi mediated adverse events
EP2627317A4 (en) *	2010-10-15	2014-08-20	Glaxo Group Ltd	MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2655374B1 (en)	2010-12-20	2019-10-23	Incyte Holdings Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US20120196933A1 (en)	2010-12-23	2012-08-02	Richard Franklin	Mexiletine prodrugs
HRP20151321T1 (hr)	2011-01-20	2016-01-29	Bionevia Pharmaceuticals Inc.	Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih
US9499462B2 (en)	2011-02-02	2016-11-22	Cognition Therapeutics, Inc.	Isolated compounds from turmeric oil and methods of use
WO2012112440A2 (en)	2011-02-14	2012-08-23	Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University	Fluorescent potassium ion sensors
BR112013020864A2 (pt)	2011-02-18	2019-09-24	Alexion Pharma Int Sarl	métodos para sintetizar derivados de precursor z de molibdopterina
CA2827673C (en)	2011-02-18	2020-10-27	Novartis Pharma Ag	Mtor/jak inhibitor combination therapy
US9108984B2 (en)	2011-03-14	2015-08-18	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MY165963A (en)	2011-06-20	2018-05-18	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
MX2014000253A (es) *	2011-07-07	2014-10-17	Arqule Inc	Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas.
EP2741747A1 (en)	2011-08-10	2014-06-18	Novartis Pharma AG	JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR102507287B1 (ko)	2011-09-02	2023-03-07	인사이트 홀딩스 코포레이션	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
JP6073545B2 (ja) *	2011-10-04	2017-02-01	横浜油脂工業株式会社	リグナン類含有微粒子及び組成物
AR088320A1 (es)	2011-10-14	2014-05-28	Incyte Corp	Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
RU2666963C2 (ru)	2012-04-13	2018-09-13	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Агрегированные частицы
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
ES2704744T3 (es)	2012-06-13	2019-03-19	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
EP2890379B1 (en)	2012-08-29	2019-04-03	Icahn School of Medicine at Mount Sinai	Benzothiazole or benzoxazole compounds as sumo activators
WO2014059314A1 (en)	2012-10-12	2014-04-17	Mayo Foundation For Medical Education And Research	Treating brain cancer using agelastatin a (aa) and analogues thereof
CN104918945B (zh)	2012-11-01	2018-01-05	因赛特公司	作为jak抑制剂的三环稠合噻吩衍生物
CN113384546A (zh)	2012-11-15	2021-09-14	因赛特公司	鲁索利替尼的缓释剂型
US9504691B2 (en) *	2012-12-06	2016-11-29	Alcon Research, Ltd.	Finafloxacin suspension compositions
JP6437452B2 (ja)	2013-01-14	2018-12-12	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr)	2013-01-15	2020-06-30	Incyte Holdings Corp	Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
EP2961533B1 (en) *	2013-02-28	2021-10-13	Sun Chemical Corporation	Continuous contained-media micromedia milling process
TWI687220B (zh)	2013-03-01	2020-03-11	美商英塞特控股公司	吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014138168A1 (en)	2013-03-06	2014-09-12	Incyte Corporation	Processes and intermediates for making a jak inhibitor
WO2014151682A1 (en)	2013-03-14	2014-09-25	Icahn School Of Medicine At Mount Sinai	Pyrimidine compounds as kinase inhibitors
MX366703B (es)	2013-03-15	2019-07-22	Incyte Holdings Corp	Heterociclos tricíclicos como inhibidores de la proteína bet.
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
SMT201900223T1 (it)	2013-05-17	2019-07-11	Incyte Corp	Sale di bipirazolo come inibitore di jak
AR096837A1 (es)	2013-07-08	2016-02-03	Incyte Corp	Heterociclos tricíclicos como inhibidores de proteínas bet
SG10201801069QA (en)	2013-08-07	2018-03-28	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
CN105658653A (zh)	2013-08-23	2016-06-08	因赛特公司	可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
DK3066085T3 (da)	2013-11-08	2020-06-02	Incyte Holdings Corp	Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
WO2015071841A1 (en)	2013-11-12	2015-05-21	Druggability Technologies Holdings Limited	Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9399640B2 (en)	2013-11-26	2016-07-26	Incyte Corporation	Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081246A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
WO2015081189A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en)	2013-12-19	2015-06-25	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
WO2015106240A1 (en)	2014-01-13	2015-07-16	The General Hospital Corporation	Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
DK3099296T3 (en)	2014-01-31	2019-04-15	Cognition Therapeutics Inc	ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en)	2014-02-13	2018-10-03	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
SI3105218T1 (sl)	2014-02-13	2019-11-29	Incyte Corp	Ciklopropilamini kot inhibitorji LSD1
MX373103B (es)	2014-02-13	2020-04-17	Incyte Holdings Corp	Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
JP6576941B2 (ja)	2014-02-28	2019-09-18	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	骨髄異形成症候群の治療のためのｊａｋ１阻害剤
PH12020552277A1 (en)	2014-04-08	2023-07-17	Incyte Holdings Corp	Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
EA034972B1 (ru)	2014-04-23	2020-04-13	Инсайт Корпорейшн	1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
CN106687462A (zh)	2014-04-30	2017-05-17	因赛特公司	Jak1抑制剂的制备方法以及其新形式
TW201625641A (zh)	2014-05-22	2016-07-16	健臻公司	Ｎａｍｐｔ抑制劑及方法
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US20170114019A1 (en)	2014-06-04	2017-04-27	Haro Pharmaceutical Inc.	18-20 member bi-polycyclic compounds
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
RU2562219C1 (ru) *	2014-06-30	2015-09-10	Закрытое акционерное общество "Путь 910"	Способ получения активированной суспензии
WO2016007727A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en)	2014-07-10	2016-04-16	Incyte Corp	Imidazopyrazines as LSD1 inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en)	2014-07-14	2016-01-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9527864B2 (en)	2014-09-15	2016-12-27	Incyte Corporation	Tricyclic heterocycles as BET protein inhibitors
CN112675178A (zh)	2014-12-22	2021-04-20	速达制药有限公司	预防和治疗血小板增多的癌症患者中的转移性疾病
ES2721286T3 (es)	2014-12-29	2019-07-30	Recordati Ireland Ltd	Derivados heterociclialquinos y su uso como moduladores de los receptores mGluR5
WO2016130501A1 (en)	2015-02-09	2016-08-18	Incyte Corporation	Aza-heteroaryl compounds as pi3k-gamma inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es)	2015-02-20	2020-04-24	Incyte Holdings Corp	Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
SI3831833T1 (sl)	2015-02-27	2023-03-31	Incyte Holdings Corporation	Postopki za pripravo inhibitorja PI3K
EP3277689B1 (en)	2015-04-03	2019-09-04	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
US20160362424A1 (en)	2015-05-11	2016-12-15	Incyte Corporation	Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016196244A1 (en)	2015-05-29	2016-12-08	Incyte Corporation	Pyridineamine compounds useful as pim kinase inhibitors
MX2017015699A (es) *	2015-06-05	2018-12-11	Lupin Ltd	Composiciones de acido diclofenaco.
LT3334709T (lt)	2015-08-12	2025-03-10	Incyte Holdings Corporation	Lsd1 inhibitoriaus druskos
US10053465B2 (en)	2015-08-26	2018-08-21	Incyte Corporation	Pyrrolopyrimidine derivatives as TAM inhibitors
TWI734699B (zh)	2015-09-09	2021-08-01	美商英塞特公司	Ｐｉｍ激酶抑制劑之鹽
EP3353156B1 (en)	2015-09-23	2021-11-03	The General Hospital Corporation	Tead transcription factor autopalmitoylation inhibitors
US9920032B2 (en)	2015-10-02	2018-03-20	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
EP3365340B1 (en)	2015-10-19	2022-08-10	Incyte Corporation	Heterocyclic compounds as immunomodulators
TW201722966A (zh)	2015-10-29	2017-07-01	英塞特公司	Bet蛋白質抑制劑之非晶固體形式
RS63359B1 (sr)	2015-11-06	2022-07-29	Incyte Corp	Heterociklična jedinjenja kao inhibitori pi3k-gama
US20170145025A1 (en)	2015-11-19	2017-05-25	Incyte Corporation	Heterocyclic compounds as immunomodulators
CN108472298B (zh)	2015-11-24	2021-04-20	深圳阿拉丁医疗科技有限公司	选择性激酶抑制剂
ES2916874T3 (es)	2015-12-17	2022-07-06	Incyte Corp	Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en)	2015-12-22	2018-08-02	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2017120194A1 (en)	2016-01-05	2017-07-13	Incyte Corporation	Pyridine and pyridimine compounds as pi3k-gamma inhibitors
EP3939570A1 (en)	2016-02-18	2022-01-19	Immune Therapeutics, Inc.	Naltrexone for treating or preventing autoimmune and inflammatory diseases
MD3436461T2 (ro)	2016-03-28	2024-05-31	Incyte Corp	Compuși pirolotriazină ca inhibitori TAM
JP6999574B2 (ja)	2016-04-22	2022-01-18	インサイト・コーポレイション	Ｌｓｄ１阻害剤の製剤
GB2554333A (en)	2016-04-26	2018-04-04	Big Dna Ltd	Combination therapy
ES2906460T3 (es)	2016-05-06	2022-04-18	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es)	2016-05-26	2022-04-12	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt)	2016-06-20	2019-04-02	Incyte Corporation	compostos heterocíclicos como imunomoduladores
KR102643344B1 (ko)	2016-06-20	2024-03-07	인사이트 코포레이션	Bet 저해제의 결정질 고체 형태
WO2017223414A1 (en)	2016-06-24	2017-12-28	Incyte Corporation	HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
MA45669A (fr)	2016-07-14	2019-05-22	Incyte Corp	Composés hétérocycliques utilisés comme immunomodulateurs
US20180055835A1 (en)	2016-08-25	2018-03-01	Immune Therapeutics Inc.	Method for Treating And Preventing Protozoal Infections
ES2941716T3 (es)	2016-08-29	2023-05-25	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
UA125650C2 (uk)	2016-09-09	2022-05-11	Інсайт Корпорейшн	Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
TW201811799A (zh)	2016-09-09	2018-04-01	美商英塞特公司	吡唑并嘧啶化合物及其用途
US10280164B2 (en)	2016-09-09	2019-05-07	Incyte Corporation	Pyrazolopyridone compounds and uses thereof
ES2899402T3 (es)	2016-12-22	2022-03-11	Incyte Corp	Derivados de piridina como inmunomoduladores
WO2018119263A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119286A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Bicyclic heteroaromatic compounds as immunomodulators
EP3558990B1 (en)	2016-12-22	2022-08-10	Incyte Corporation	Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
ES2874756T3 (es)	2016-12-22	2021-11-05	Incyte Corp	Derivados de triazolo[1,5-A]piridina como inmunomoduladores
AU2017382870B2 (en)	2016-12-22	2022-03-24	Incyte Corporation	Benzooxazole derivatives as immunomodulators
US20180228786A1 (en)	2017-02-15	2018-08-16	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
EP3634394B1 (en)	2017-05-15	2025-12-24	Cognition Therapeutics, Inc.	Compositions for treating neurodegenerative diseases
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3066193A1 (en)	2017-06-29	2019-01-03	Recordati Industria Chimica E Farmaceutica Spa	Heterocyclylmethylidene derivatives and their use as modulators of mglur5 receptors
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
WO2019051469A1 (en)	2017-09-11	2019-03-14	Krouzon Pharmaceuticals, Inc.	Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
SI3687996T1 (sl)	2017-09-27	2022-04-29	Incyte Corporation	Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
KR20240152947A (ko)	2017-10-18	2024-10-22	인사이트 코포레이션	Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
WO2019084459A1 (en)	2017-10-26	2019-05-02	Xynomic Pharmaceuticals, Inc.	CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
PL3723760T3 (pl) *	2017-12-14	2025-10-20	SpecGx LLC	Jednoetapowy sposób mielenia w celu wytworzenia zmikronizowanych estrów paliperydonu
WO2019126505A1 (en)	2017-12-21	2019-06-27	Incyte Corporation	3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
JP7447020B2 (ja)	2018-01-26	2024-03-11	レコルダーティインドゥストリアキミカエファルマチェウチカソシエタ・ペル・アチオニ	トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用
EA202091830A1 (ru)	2018-01-30	2020-12-29	Инсайт Корпорейшн	Способы и промежуточные соединения для получения ингибитора jak
IL311485B1 (en)	2018-02-16	2026-01-01	Incyte Corp	JAK1 pathway inhibitors for the treatment of cytokine-related disorders
US10800761B2 (en)	2018-02-20	2020-10-13	Incyte Corporation	Carboxamide compounds and uses thereof
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
WO2019164847A1 (en)	2018-02-20	2019-08-29	Incyte Corporation	Indazole compounds and uses thereof
BR122023024273A2 (pt)	2018-02-27	2024-02-20	Incyte Corporation	Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
BR112020018094A2 (pt)	2018-03-08	2020-12-22	Incyte Corporation	Compostos de aminopirazina diol como inibidores de pi3k-¿
MD3773593T2 (ro)	2018-03-30	2024-10-31	Incyte Corp	Tratament hidradenitei supurative utilizând inhibitori ai JAK
CR20200520A (es)	2018-03-30	2021-03-09	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
US11220510B2 (en)	2018-04-09	2022-01-11	Incyte Corporation	Pyrrole tricyclic compounds as A2A / A2B inhibitors
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
CR20200590A (es)	2018-05-04	2021-04-26	Incyte Corp	Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
WO2019217821A1 (en)	2018-05-11	2019-11-14	Incyte Corporation	Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
WO2019222677A1 (en)	2018-05-18	2019-11-21	Incyte Corporation	Fused pyrimidine derivatives as a2a / a2b inhibitors
ES2929415T3 (es)	2018-05-25	2022-11-29	Incyte Corp	Compuestos heterocíclicos tricíclicos como activadores de STING
CA3101323A1 (en)	2018-06-01	2019-12-05	Incyte Corporation	Dosing regimen for the treatment of pi3k related disorders
MD3813800T2 (ro)	2018-06-29	2025-10-31	Incyte Corp	Formulări de inhibitor al AXL/MER
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
GEP20237548B (en)	2018-07-05	2023-10-10	Incyte Corp	Fused pyrazine derivatives as a2a /a2b inhibitors
GB2575490A (en)	2018-07-12	2020-01-15	Recordati Ind Chimica E Farmaceutica Spa	P2X3 receptor antagonists
US10875872B2 (en)	2018-07-31	2020-12-29	Incyte Corporation	Heteroaryl amide compounds as sting activators
US11008344B2 (en)	2018-07-31	2021-05-18	Incyte Corporation	Tricyclic heteroaryl compounds as STING activators
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
WO2020047198A1 (en)	2018-08-31	2020-03-05	Incyte Corporation	Salts of an lsd1 inhibitor and processes for preparing the same
CR20250050A (es)	2018-09-05	2025-03-19	Incyte Corp	Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
ES2973117T3 (es)	2018-09-25	2024-06-18	Incyte Corp	Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CA3117969A1 (en)	2018-10-31	2020-05-07	Incyte Corporation	Combination therapy for treatment of hematological diseases
US11078204B2 (en)	2018-11-13	2021-08-03	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Substituted heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en)	2018-11-13	2021-11-02	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors
US11596692B1 (en)	2018-11-21	2023-03-07	Incyte Corporation	PD-L1/STING conjugates and methods of use
CA3123596A1 (en)	2018-12-19	2020-06-25	Incyte Corporation	Jak1 pathway inhibitors for the treatment of gastrointestinal disease
CA3124088A1 (en)	2018-12-20	2020-06-25	Incyte Corporation	Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
US12129267B2 (en)	2019-01-07	2024-10-29	Incyte Corporation	Heteroaryl amide compounds as sting activators
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020168197A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
MA55201A (fr)	2019-03-05	2022-01-12	Incyte Corp	Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
WO2020180959A1 (en)	2019-03-05	2020-09-10	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
EP3937943A4 (en)	2019-03-15	2022-12-07	The General Hospital Corporation	NEW SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
WO2020223235A1 (en)	2019-04-29	2020-11-05	Incyte Corporation	Mini-tablet dosage forms of ponatinib
WO2020223558A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
MX2022001562A (es)	2019-08-06	2022-04-26	Incyte Corp	Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
CA3148115A1 (en)	2019-08-08	2021-02-11	Laekna Limited	Method of treating cancer
EP4010342A1 (en)	2019-08-09	2022-06-15	Incyte Corporation	Salts of a pd-1/pd-l1 inhibitor
TW202115024A (zh)	2019-08-14	2021-04-16	美商英塞特公司	作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
US20210061809A1 (en)	2019-08-26	2021-03-04	Incyte Corporation	Triazolopyrimidines as a2a / a2b inhibitors
WO2021067217A1 (en)	2019-09-30	2021-04-08	Incyte Corporation	Pyrido[3,2-d]pyrimidine compounds as immunomodulators
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
AU2020364007A1 (en)	2019-10-11	2022-04-28	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076124A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11992490B2 (en)	2019-10-16	2024-05-28	Incyte Corporation	Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
BR112022009031A2 (pt)	2019-11-11	2022-10-11	Incyte Corp	Sais e formas cristalinas de um inibidor de pd-1/pd-l1
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
MX2022008208A (es)	2020-01-03	2022-10-21	Incyte Corp	Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
US20210269434A1 (en)	2020-01-10	2021-09-02	Incyte Corporation	Tricyclic compounds as inhibitors of kras
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021150613A1 (en)	2020-01-20	2021-07-29	Incyte Corporation	Spiro compounds as inhibitors of kras
WO2021158891A1 (en)	2020-02-06	2021-08-12	Incyte Corporation	Salts and solid forms and processes of preparing a pi3k inhibitor
EP4114401A1 (en)	2020-03-06	2023-01-11	Incyte Corporation	Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021198962A1 (en)	2020-04-01	2021-10-07	Cytocom Inc.	Method for treating viral diseases
CA3179692A1 (en)	2020-04-16	2021-10-21	Incyte Corporation	Fused tricyclic kras inhibitors
US11739102B2 (en)	2020-05-13	2023-08-29	Incyte Corporation	Fused pyrimidine compounds as KRAS inhibitors
GB202008135D0 (en)	2020-05-29	2020-07-15	Neolife Int Llc	Dietary supplements
FI4157831T3 (fi)	2020-06-02	2024-12-02	Incyte Corp	Menetelmiä jak1-estäjän valmistamiseksi
DK4161528T3 (da)	2020-06-03	2025-11-24	Incyte Corp	Kombination af ruxolitinib med incb057643 til anvendelse ved behandling af myeloproliferative neoplasmer
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
CN115956081A (zh)	2020-06-12	2023-04-11	因赛特公司	具有作为alk2抑制剂的活性的咪唑并哒嗪化合物
WO2021257863A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en)	2020-07-02	2023-09-26	Incyte Corporation	Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (it)	2020-07-02	2025-09-12	Incyte Corp	Composti di urea triciclici come inibitori di v617f di jak2
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
US11999752B2 (en)	2020-08-28	2024-06-04	Incyte Corporation	Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en)	2020-10-02	2022-04-07	Incyte Corporation	Bicyclic dione compounds as inhibitors of kras
KR102271247B1 (ko) *	2020-11-04	2021-06-30	삼천당제약주식회사	안과용 현탁액 조성물의 제조방법
US11780836B2 (en)	2020-11-06	2023-10-10	Incyte Corporation	Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en)	2020-11-06	2022-05-12	Incyte Corporation	Crystalline form of a pd-1/pd-l1 inhibitor
US11866434B2 (en)	2020-11-06	2024-01-09	Incyte Corporation	Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
CA3203587A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022125670A1 (en)	2020-12-08	2022-06-16	Incyte Corporation	Jak1 pathway inhibitors for the treatment of vitiligo
TW202241420A (zh)	2020-12-18	2022-11-01	美商英塞特公司	Ｐｄ－ｌ１抑制劑之口服調配物
WO2022140231A1 (en)	2020-12-21	2022-06-30	Incyte Corporation	Deazaguaine compounds as jak2 v617f inhibitors
MX2023007850A (es)	2020-12-29	2023-09-11	Incyte Corp	Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
EP4274578A1 (en)	2021-01-11	2023-11-15	Incyte Corporation	Combination therapy comprising jak pathway inhibitor and rock inhibitor
AR125273A1 (es)	2021-02-25	2023-07-05	Incyte Corp	Lactamas espirocíclicas como inhibidores de jak2 v617f
GB202103100D0 (en)	2021-03-05	2021-04-21	Suda Pharmaceuticals Ltd	Mitigating the off-target pharmacology of anagrelide in the treatment of thrombocytosis in various diseases
EP4308565A4 (en)	2021-03-19	2025-01-01	Cognition Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
WO2022204112A1 (en)	2021-03-22	2022-09-29	Incyte Corporation	Imidazole and triazole kras inhibitors
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022235617A1 (en)	2021-05-03	2022-11-10	Incyte Corporation	Ruxolitinib for the treatment of prurigo nodularis
RS67455B1 (sr)	2021-05-03	2025-12-31	Incyte Corp	Inhibitori jak1 puta za lečenje prurigo nodularisa
EP4352059A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
EP4363408A1 (en)	2021-07-02	2024-05-08	Ascletics Bioscience Co., Ltd.	Heterocyclic compounds as immunomodulators of pd-l1 interactions
MX2024000357A (es)	2021-07-07	2024-02-12	Incyte Corp	Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
US12600717B2 (en)	2021-07-14	2026-04-14	Incyte Corporation	Tricyclic compounds as inhibitors of KRAS
JP7776616B2 (ja)	2021-08-17	2025-11-26	アスカレシスバイオサイエンスカンパニーリミテッド	Ｐｄ－ｌ１相互作用の免疫調節剤としての化合物
US12441742B2 (en)	2021-08-31	2025-10-14	Incyte Corporation	Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (en)	2021-09-21	2023-03-30	Incyte Corporation	Hetero-tricyclic compounds as inhibitors of kras
CN113908932A (zh) *	2021-09-22	2022-01-11	浙江工业大学	一种磁性粉体连续细化及级分的方法与装置
CA3234375A1 (en)	2021-10-01	2023-04-06	Incyte Corporation	Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en)	2021-10-14	2023-04-20	Incyte Corporation	Quinoline compounds as inhibitors of kras
TW202329937A (zh)	2021-12-03	2023-08-01	美商英塞特公司	雙環胺ｃｋ１２抑制劑
WO2023107705A1 (en)	2021-12-10	2023-06-15	Incyte Corporation	Bicyclic amines as cdk12 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
CA3244187A1 (en)	2021-12-22	2023-06-29	Incyte Corporation	SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND THEIR METHODS OF PREPARATION
CN114289159B (zh) *	2021-12-29	2023-06-06	湖北华世通生物医药科技有限公司	碳酸司维拉姆的后处理方法及其制备方法
US20250066710A1 (en) *	2022-01-06	2025-02-27	Athem Llc	A single-use system and method for continuous homogenization or lysis
EP4490151A1 (en)	2022-03-07	2025-01-15	Incyte Corporation	Solid forms, salts, and processes of preparation of a cdk2 inhibitor
US20250177352A1 (en)	2022-03-14	2025-06-05	Laekna Limited	Combination treatment for cancer
CN119173514A (zh)	2022-03-17	2024-12-20	因赛特公司	作为jak2 v617f抑制剂的三环脲化合物
PE20250927A1 (es)	2022-06-08	2025-04-02	Incyte Corp	Compuestos triciclicos de triazolo como inhibidores de dgk
AR129675A1 (es)	2022-06-22	2024-09-18	Incyte Corp	Inhibidores de cdk12 de aminas biciclicas
WO2024015731A1 (en)	2022-07-11	2024-01-18	Incyte Corporation	Fused tricyclic compounds as inhibitors of kras g12v mutants
US12600722B2 (en)	2022-07-18	2026-04-14	Incyte Corporation	Tetracyclic compounds as DGK inhibitors
US12600723B2 (en)	2022-07-18	2026-04-14	Incyte Corporation	Tetracyclic compounds as DGK inhibitors
IL318652A (en)	2022-08-05	2025-03-01	Incyte Corp	Treatment of urticaria with JAK inhibitors
WO2024086273A1 (en)	2022-10-21	2024-04-25	Incyte Corporation	Tricyclic urea compounds as jak2 v617f inhibitors
AR131099A1 (es)	2022-11-18	2025-02-19	Incyte Corp	Fluoroalquenos heteroarílicos como inhibidores de dgk
CN116078516A (zh) *	2022-12-09	2023-05-09	贵阳永亮未来新能源发展有限公司	一种制备纳米级硅的设备
EP4389746A3 (en)	2022-12-21	2024-07-03	Recordati Industria Chimica E Farmaceutica SPA	P2x3 receptor antagonists
AR131101A1 (es)	2023-01-12	2025-02-19	Incyte Corp	Heteroarilfluoroalquenos como inhibidores de dgk
TW202440086A (zh)	2023-03-13	2024-10-16	美商英塞特公司	作為激酶抑制劑之雙環脲
TW202438061A (zh)	2023-03-16	2024-10-01	美商英塞特公司	用於治療氣喘之ｊａｋ１路徑抑制劑
WO2024220532A1 (en)	2023-04-18	2024-10-24	Incyte Corporation	Pyrrolidine kras inhibitors
GEAP202616866A (en)	2023-04-18	2026-02-10	Incyte Corp	2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024254245A1 (en)	2023-06-09	2024-12-12	Incyte Corporation	Bicyclic amines as cdk2 inhibitors
US20250084063A1 (en)	2023-08-18	2025-03-13	Incyte Corporation	Bicyclic heterocycles as mrgprx2 antagonists
WO2025043151A2 (en)	2023-08-24	2025-02-27	Incyte Corporation	Bicyclic dgk inhibitors
US20250163079A1 (en)	2023-11-01	2025-05-22	Incyte Corporation	Kras inhibitors
WO2025096373A1 (en)	2023-11-02	2025-05-08	Incyte Corporation	Ruxolitinib for use in the treatment of prurigo nodularis
TW202523667A (zh)	2023-12-05	2025-06-16	美商英塞特公司	作為ｄｇｋ抑制劑之三環三唑并化合物
US20250186450A1 (en)	2023-12-06	2025-06-12	Incyte Corporation	COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
US20250195536A1 (en)	2023-12-13	2025-06-19	Incyte Corporation	Bicyclooctane kras inhibitors
US20250243208A1 (en)	2024-01-25	2025-07-31	Incyte Corporation	Bicyclic heterocycles as mrgprx2 antagonists
WO2026030341A1 (en)	2024-07-29	2026-02-05	Cognition Therapeutics, Inc.	Zervimesine for treating neurodegenerative disease
WO2026060143A1 (en)	2024-09-11	2026-03-19	Incyte Corporation	Kras inhibitors
WO2026064542A1 (en)	2024-09-18	2026-03-26	Cognition Therapeutics, Inc.	2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms
WO2026076207A1 (en)	2024-10-04	2026-04-09	Incyte Corporation	Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4076347A (en) *	1976-07-21	1978-02-28	Dayco Corporation	Antifriction nylon member
US4547534A (en) *	1983-03-18	1985-10-15	Memorex Corporation	Method to disperse fine solids without size reduction
US4768366A (en) *	1987-04-30	1988-09-06	Tadeusz Sendzimir	Wide strip mill using pressure elements
NZ248813A (en) *	1992-11-25	1995-06-27	Eastman Kodak Co	Polymeric grinding media used in grinding pharmaceutical substances
GB9726543D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel compositions
EP1185371B2 (en) *	1999-06-01	2008-11-12	Elan Pharma International Limited	Small-scale mill and method thereof
GB9920148D0 (en) *	1999-08-25	1999-10-27	Smithkline Beecham Plc	Novel composition

2001
- 2001-06-22 AT AT01984051T patent/ATE273695T1/de active
- 2001-06-22 AU AU2002215608A patent/AU2002215608B2/en not_active Ceased
- 2001-06-22 MX MXPA03000051A patent/MXPA03000051A/es active IP Right Grant
- 2001-06-22 IL IL15323101A patent/IL153231A0/xx active IP Right Grant
- 2001-06-22 DE DE60105023T patent/DE60105023T2/de not_active Expired - Lifetime
- 2001-06-22 PL PL359065A patent/PL202623B1/pl unknown
- 2001-06-22 CA CA002413330A patent/CA2413330A1/en not_active Abandoned
- 2001-06-22 EP EP01984051A patent/EP1294358B1/en not_active Expired - Lifetime
- 2001-06-22 BR BR0111747-5A patent/BR0111747A/pt not_active Application Discontinuation
- 2001-06-22 CN CNB018119328A patent/CN1321628C/zh not_active Expired - Fee Related
- 2001-06-22 AU AU1560802A patent/AU1560802A/xx not_active Withdrawn
- 2001-06-22 KR KR1020027017942A patent/KR100786927B1/ko not_active Expired - Fee Related
- 2001-06-22 CZ CZ20024263A patent/CZ303572B6/cs not_active IP Right Cessation
- 2001-06-22 HU HU0301583A patent/HU230396B1/hu not_active IP Right Cessation
- 2001-06-22 NZ NZ522783A patent/NZ522783A/en not_active IP Right Cessation
- 2001-06-22 US US10/311,918 patent/US20040089753A1/en not_active Abandoned
- 2001-06-22 PT PT01984051T patent/PT1294358E/pt unknown
- 2001-06-22 SI SI200130212T patent/SI1294358T1/xx unknown
- 2001-06-22 ES ES01984051T patent/ES2225624T3/es not_active Expired - Lifetime
- 2001-06-22 JP JP2002504978A patent/JP4188078B2/ja not_active Expired - Fee Related
- 2001-06-22 WO PCT/EP2001/007085 patent/WO2002000196A2/en not_active Ceased
- 2001-06-26 MY MYPI20013005A patent/MY128806A/en unknown
- 2001-06-26 TW TW090115341A patent/TWI290836B/zh not_active IP Right Cessation
- 2001-06-26 AR ARP010103036A patent/AR029284A1/es unknown
2002
- 2002-12-02 IL IL153231A patent/IL153231A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026120A patent/NO333747B1/no not_active IP Right Cessation
2006
- 2006-06-01 US US11/444,801 patent/US20060214037A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1055242A1 (en)	2004-01-02
KR100786927B1 (ko)	2007-12-17
WO2002000196A2 (en)	2002-01-03
ATE273695T1 (de)	2004-09-15
JP4188078B2 (ja)	2008-11-26
PL359065A1 (pl)	2004-08-23
EP1294358A2 (en)	2003-03-26
IL153231A0 (en)	2003-07-06
TWI290836B (en)	2007-12-11
SI1294358T1 (en)	2004-12-31
PL202623B1 (pl)	2009-07-31
HUP0301583A2 (en)	2003-08-28
CN1321628C (zh)	2007-06-20
CZ303572B6 (cs)	2012-12-12
ES2225624T3 (es)	2005-03-16
EP1294358B1 (en)	2004-08-18
DE60105023D1 (de)	2004-09-23
AR029284A1 (es)	2003-06-18
MXPA03000051A (es)	2003-08-19
WO2002000196A3 (en)	2002-06-27
DE60105023T2 (de)	2005-08-18
US20060214037A1 (en)	2006-09-28
US20040089753A1 (en)	2004-05-13
MY128806A (en)	2007-02-28
KR20030018013A (ko)	2003-03-04
CN1438876A (zh)	2003-08-27
HU230396B1 (hu)	2016-04-28
CA2413330A1 (en)	2002-01-03
JP2004501182A (ja)	2004-01-15
BR0111747A (pt)	2003-07-08
IL153231A (en)	2008-06-05
NO20026120D0 (no)	2002-12-19
AU2002215608B2 (en)	2004-12-09
NO20026120L (no)	2003-01-27
NZ522783A (en)	2004-07-30
PT1294358E (pt)	2004-12-31
CZ20024263A3 (cs)	2003-06-18
AU1560802A (en)	2002-01-08

Legal Events

Date	Code	Title	Description
2020-01-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO333747B1 (no)	2013-09-09	Vat maleprosess
AU2002215608A1 (en)	2002-03-28	Wet milling process
Paredes et al.	2020	Ricobendazole nanocrystals obtained by media milling and spray drying: pharmacokinetic comparison with the micronized form of the drug
CN100457090C (zh)	2009-02-04	磨制颗粒
EP1372404B1 (en)	2007-08-22	Process for the deagglomeration and the homogeneous dispersion of starch particles
AU2003295704B2 (en)	2008-05-08	Methods and apparatus for making particles using spray dryer and in-line jet mill
KR20080110807A (ko)	2008-12-19	마이크로 분쇄 및 마이크로-시드상의 결정화에 의한 결정성유기 미세입자 조성물의 생성 방법과 장치 및 이의 용도
CA2631492A1 (en)	2007-06-21	Processes for making particle-based pharmaceutical formulations for oral administration
Braig et al.	2019	Enhanced dissolution of naproxen from pure-drug, crystalline nanoparticles: A case study formulated into spray-dried granules and compressed tablets
TW200826973A (en)	2008-07-01	Method of micronization
Dickey et al.	1998	Zein Batch Extraction from Dry‐Milled Corn: Cereal Disintegration by Dissolving Fluid Shear
HK1055242B (en)	2005-04-29	Wet milling process
US20090203789A1 (en)	2009-08-13	Fast Dissolution Amino Acid Composition
JP6453876B2 (ja)	2019-01-16	メタキサロンの製剤
JP2008510779A (ja)	2008-04-10	液体推進剤の存在下で難溶性医薬をミリングするための方法
Nerella et al.	2024	Design, development, and optimization of sumatriptan loaded ethosomal intra-nasal nanogel for brain targeting
WO2002094223A2 (en)	2002-11-28	Formulation containing halofantrine hydrochloride
CN116159023A (zh)	2023-05-26	一种生物利用度高的阿托伐醌混悬液及其制备方法
Rattes et al.	2004	Spray-drying as a method for microparticulate modified release systems preparation
Castor	2005	Protein Nanoparticles
WO2002072064A2 (en)	2002-09-19	Granular composition comprising an active compound and a cellulose ether and the use thereof